Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exit Interview: Medtronic CEO Hawkins Sees Burgeoning Challenges, Opportunities

This article was originally published in The Gray Sheet

Executive Summary

In an environment impacted by health care reform and an increasingly complex reimbursement arena, device trials must demonstrate both clinical and economic utility equally, said Bill Hawkins, who recently ended his tenure as Medtronic’s chairman and CEO.

You may also be interested in...



Medtronic Mines GE For New Chief; Omar Ishrak Starts In June

Medtronic's incoming CEO has run a similarly sized medical technology business in terms of sales for the past two years, albeit with a focus on diagnostic and monitoring tools rather than therapeutic technologies.

Fracture Data Spurs Medtronic To Suspend Sales Of Fidelis ICD Lead

Medtronic's decision to halt worldwide distribution of its Sprint Fidelis defibrillator leads has attracted congressional scrutiny of the company's response to data showing the leads were vulnerable to fracture

RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.

 

 

UsernamePublicRestriction

Register

MT030258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel